+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.

Age: 18Years +All GendersPhase 3
227 locations
E

Actively Recruiting

The trial investigates how well AZD6234 works and its safety in adults who have Type 2 Diabetes Mellitus along with obesity or excess weight. This Phase III, global, randomized, double-blind study compares AZD6234 to a placebo to measure changes in body weight over 68 weeks of treatment. The study aims to better understand weight loss effects and related health changes in this population. Participants will be randomly assigned to one of three groups two different doses of AZD6234 or a placebo. The treatments are given by weekly subcutaneous injections. The study will last 68 weeks, during which participants receive their assigned injections and are monitored regularly for effectiveness and safety. Throughout the study, participants will attend multiple visits for evaluations, including body weight, waist circumference, blood pressure, and lab tests such as haemoglobin A1C and triglycerides. Some may undergo DXA scans to measure fat mass. Researchers will track changes from baseline to assess weight loss and metabolic effects. Safety and tolerability will also be monitored over the treatment period, which lasts about 68 weeks.

Age: 18Years +All GendersPhase 3
230 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
L

Actively Recruiting

Researchers are investigating maridebart cafraglutide for people with obesity or overweight to evaluate its long-term effects on weight management, safety, and tolerability. This trial is an extension of a previous study trial 20210181 and aims to provide more information about how the drug works over an extended period. It is a phase 3, randomized, double-blind study sponsored by Amgen. Participants will receive different doses of maridebart cafraglutide or placebo depending on their treatment in the previous trial. Some will continue with low dose every 4 weeks, others will be re-randomized to receive medium or high doses on schedules of every 4, 8, or 12 weeks, or placebo injections every 4 weeks. Participants who had placebo before will undergo a dose-escalation phase before starting the high dose treatment. During the study, participants will be monitored for changes in body weight, waist circumference, quality of life, and any side effects or adverse events over about 48 weeks of treatment. The trial will assess how well weight loss is maintained and record any treatment-emergent adverse events up to 60 weeks. Participants will have regular visits for injections and safety assessments throughout the study period.

Age: 18Years - 99YearsAll GendersPhase 3
92 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of ABBV-295, a long-acting amylin analog, for adults with obesity or overweight who also have weight-related health conditions. The study aims to compare different doses of ABBV-295 with a placebo to see how well they reduce body weight by Week 32. This phase 2 trial involves about 360 adult participants across multiple sites in the United States and Puerto Rico. Participants will be randomly assigned to receive one of several doses of ABBV-295 or a placebo. The treatment is given as subcutaneous injections using pre-filled syringes. Dose escalation will occur during the 52-week Double-Blind Period until reaching a maintenance dose. Participants will not know which treatment they receive, and all groups follow a similar dosing schedule. Throughout the study, participants will attend regular visits at clinics or hospitals for medical assessments, blood tests, and questionnaires to monitor weight changes and any side effects. The primary outcomes include the percentage change in body weight from baseline to Week 32 and the number of participants experiencing adverse events up to Week 52. The study lasts for 52 weeks of treatment with ongoing safety monitoring.

Age: 18Years - 75YearsAll GendersPhase 2
64 locations